Thursday, 5 November 2026European Markets

BENETEAU And TFF GROUP Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - beneteau (ben.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
beneteau (ben.pa) €13.68 5.46% 20.34%
tff group (tff.pa) €42.80 1.42% 11.88%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. beneteau (ben.pa)

5.46% forward dividend yield and 20.34% return on equity

bénéteau s.a. designs, manufactures, and sells boats and leisure homes in france and internationally. it provides boats under the beneteau, jeanneau, lagoon, prestige, four winns, scarab, wellcraft, excess, and delphia brand names; and leisure homes under the irm, o'hara, and coco sweet brand names. the company also offers bandofbaots.com, a community services platform for purchase and sale of new or used boats; lease purchase, credit, and insurance services through sgb finance; and inventory and retail finance solutions. bénéteau s.a. was founded in 1884 and is headquartered in saint-gilles-croix-de-vie, france. bénéteau s.a. operates as a subsidiary of beri 21 s.a.

earnings per share

as for profitability, beneteau has a trailing twelve months eps of €2.38.

pe ratio

beneteau has a trailing twelve months price to earnings ratio of 5.75. meaning, the purchaser of the share is investing €5.75 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.34%.

volatility

beneteau's last week, last month's, and last quarter's current intraday variation average was a negative 0.31%, a positive 0.21%, and a positive 1.44%.

beneteau's highest amplitude of average volatility was 0.92% (last week), 1.62% (last month), and 1.44% (last quarter).

yearly top and bottom value

beneteau's stock is valued at €13.68 at 02:30 est, way under its 52-week high of €16.60 and way higher than its 52-week low of €10.52.

volume

today's last reported volume for beneteau is 47086 which is 59.25% below its average volume of 115563.

more news about beneteau.

2. tff group (tff.pa)

1.42% forward dividend yield and 11.88% return on equity

tff group, together with its subsidiaries, manufactures and distributes barrels and wood products for the aging of wines and alcohols in france, rest of europe, the united states, asia, and internationally. the company offers forestry and logging, stave milling, whisky and bourbon cooperages, cask making, wood and oenological products, and stainless-steel containers. it primarily serves wine, bourbon, and whisky markets. the company was formerly known as tonnellerie françois frères. tff group was founded in 1910 and is based in saint-romain-de-colbosc, france.

earnings per share

as for profitability, tff group has a trailing twelve months eps of €2.44.

pe ratio

tff group has a trailing twelve months price to earnings ratio of 17.54. meaning, the purchaser of the share is investing €17.54 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.88%.

yearly top and bottom value

tff group's stock is valued at €42.80 at 02:30 est, below its 52-week high of €47.50 and way higher than its 52-week low of €37.70.

more news about tff group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com